Trial Profile
Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Capecitabine; Carboplatin; Docetaxel; Fluorouracil; Folinic acid; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2023 Results (n=11) of long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers, presented at the 2023 Gastrointestinal Cancers Symposium
- 17 Jun 2022 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Results of molecular profiling predictng first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma, presented at the 113th Annual Meeting of the American Association for Cancer Research